Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has a good clinical efficacy in lung adenocarcinoma harboring some types of gene mutation in the tyrosine kinase domain of EGFR (4). The gene discussed is EGFR; the disease is lung adenocarcinoma.